BioMarin Pharmaceutical Inc. $BMRN Stake Lowered by Danske Bank A S

Key Points

• Danske Bank cut its BioMarin stake by 93.8% in Q4, selling 108,424 shares and retaining 7,200 shares worth roughly $428,000.
• Mixed Q1 results and guidance: BioMarin raised FY‑2026 revenue guidance (including newly added products) but reported a Q1 EPS miss ($0.76 vs. ~$0.94) and set FY‑2026 EPS guidance slightly below consensus, a combination that pressured the stock (down ~4%).
• Insider and institutional moves: Two EVPs sold a combined ~22,812 shares, Invesco boosted its holding to 618,835 shares (~$34M), and institutions now own about 98.7% of the stock while insiders hold 0.85%.

Danske Bank A S cut its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 93.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,200 shares of the biotechnology company's stock after selling 108,424 shares during the quarter. Danske Bank A S's holdings in BioMarin Pharmaceutical were worth $428,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of BMRN. NewEdge Advisors LLC grew its stake in BioMarin Pharmaceutical by 11.5% in the first quarter. NewEdge Advisors LLC now owns 3,769 shares of the biotechnology company's stock valued at $266,000 after purchasing an additional 388 shares in the last quarter. Empowered Funds LLC raised its stake in shares of BioMarin Pharmaceutical by 207.4% during the 1st quarter. Empowered Funds LLC now owns 12,023 shares of the biotechnology company's stock worth $850,000 after purchasing an additional 8,112 shares in the last quarter. Focus Partners Wealth raised its stake in shares of BioMarin Pharmaceutical by 70.2% during the 1st quarter. Focus Partners Wealth now owns 11,817 shares of the biotechnology company's stock worth $835,000 after purchasing an additional 4,876 shares in the last quarter. Sivia Capital Partners LLC lifted its holdings in shares of BioMarin Pharmaceutical by 33.0% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,439 shares of the biotechnology company's stock valued at $244,000 after buying an additional 1,102 shares during the last quarter. Finally, Invesco Ltd. grew its stake in shares of BioMarin Pharmaceutical by 23.5% in the 2nd quarter. Invesco Ltd. now owns 618,835 shares of the biotechnology company's stock valued at $34,017,000 after buying an additional 117,617 shares in the last quarter. 98.71% of the stock is currently owned by hedge funds and other institutional investors.

BioMarin Pharmaceutical Stock Down 4.0%

Shares of BMRN stock opened at $53.24 on Wednesday. The stock's 50 day simple moving average is $56.71 and its 200 day simple moving average is $56.32. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.50 and a current ratio of 5.21. BioMarin Pharmaceutical Inc. has a twelve month low of $50.76 and a twelve month high of $66.28. The company has a market capitalization of $10.29 billion, a price-to-earnings ratio of 38.86, a PEG ratio of 0.56 and a beta of 0.23.

Insider Activity at BioMarin Pharmaceutical

In other news, EVP Gregory R. Friberg sold 6,326 shares of the business's stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $60.38, for a total value of $381,963.88. Following the completion of the sale, the executive vice president directly owned 37,578 shares in the company, valued at approximately $2,268,959.64. The trade was a 14.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Charles Greg Guyer sold 16,486 shares of the company's stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $60.46, for a total transaction of $996,743.56. Following the sale, the executive vice president directly owned 79,953 shares of the company's stock, valued at approximately $4,833,958.38. This represents a 17.09% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.85% of the company's stock.

Key Stories Impacting BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Company raised 2026 revenue guidance and incorporated newly added products (GALAFOLD® and POMBILITI® + OPFOLDA®), signaling faster top-line growth for FY-2026. BioMarin Reports First Quarter 2026 Financial and Operating Results
• Positive Sentiment: Some sell-side firms remain constructive: Morgan Stanley keeps an overweight rating (PT cut only marginally to $119) and Sanford Bernstein retains an outperform stance despite lowering its PT — these notes support upside expectations from analysts. Benzinga
• Neutral Sentiment: Q1 revenue came in roughly in line/beat consensus (~$766M vs. ~$752M), showing modest year-over-year growth; this underpins the revenue-guidance raise but the market is focused more on profitability. BioMarin Q1 results (MarketBeat)
• Neutral Sentiment: Company updated FY-2026 EPS guidance to ~$4.85–5.05 (slightly below consensus) while raising revenue guidance to roughly $3.825–3.925B — mixed signal: revenue growth acceleration vs. EPS pressure. BioMarin Q1 Earnings Miss, Sales Beat, '26 Revenue Guidance Raised
• Negative Sentiment: EPS missed expectations ($0.76 vs. consensus ~$0.94); management cited charges and higher costs that reduced profitability and drove the earnings shortfall. BioMarin Q1 Earnings Lag Estimates
• Negative Sentiment: Market reaction likely amplified by investor focus on margins and near-term profitability; earnings call/transcript highlights cost and charge items that pressured EPS. BioMarin Q1 2026 Earnings Call Transcript

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Oppenheimer dropped their price objective on BioMarin Pharmaceutical from $98.00 to $95.00 and set an "outperform" rating on the stock in a report on Tuesday, February 24th. Bank of America decreased their target price on shares of BioMarin Pharmaceutical from $97.00 to $85.00 and set a "buy" rating for the company in a research report on Wednesday, March 11th. Piper Sandler dropped their price target on shares of BioMarin Pharmaceutical from $122.00 to $84.00 and set an "overweight" rating on the stock in a research note on Friday, February 6th. Royal Bank Of Canada restated a "sector perform" rating and set a $66.00 price target on shares of BioMarin Pharmaceutical in a report on Tuesday. Finally, Wells Fargo & Company lifted their price objective on shares of BioMarin Pharmaceutical from $70.00 to $75.00 and gave the company an "overweight" rating in a research note on Wednesday, February 18th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $90.32.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company's commercial portfolio includes several approved therapies targeting inherited disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.